Dergiler / Dicle Tıp Dergisi / 2022 / Cilt: 49 - Sayı: 1

A Novel Diagnostic Marker in Pulmonary Thromboembolism? Platelet-Derived Growth Factor –β

Sayfa
1–11
Yayın Tarihi
2022-03-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, PDGF-B cannot be used as a marker to predict prognosis

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Pulmonary thromboembolism (PTE) is a condition characterized by severe cardiopulmonary injury.
📊
Temel Bulgular & Veri:In the present study, we aimed to investigate whether plasma PDGF-B levels increase in patients with PTE and the diagnostic value of PDGF-B in PTE along with its relationship with mortality.
💡
Sonuç & Katkı:However, PDGF-B cannot be used as a marker to predict prognosis
🔬Tür:Araştırma Makalesi
📍Kapsam:2020 Verileri
⚙️Değişkenler:Biomarker · mortality · PDGF-B

Özet

Objective: Pulmonary thromboembolism (PTE) is a condition characterized by severe cardiopulmonary injury. There is a need for a cheap and reliable biochemical marker, which is also easily and rapidly accessible, with high specificity and sensitivity in the diagnosis of PTE. The PDGF ligand receptor system plays a role in the development of pulmonary hypertension and contributes to thickening of the vascular wall and increasing the wall tension. In the present study, we aimed to investigate whether plasma PDGF-B levels increase in patients with PTE and the diagnostic value of PDGF-B in PTE along with its relationship with mortality. Methods: This prospective clinical study was conducted in the emergency department of a tertiary university hospital between March 1st, 2020 and March 1st, 2021. A total of 44 patients diagnosed as having PTE in the emergency department (patient group) and 34 healthy volunteers without any chronic disease (control group) were included in our study. Results: The PDGF-β levels of the patients diagnosed as having PTE in the ED were found to be significantly higher than those of patients in the control group (Z=-2.015, p=0.044). There was no significant linear relationship between PDGF-β levels and age, gender, presence of chronic disease, systolic and diastolic blood pressure as well as peak heart rate, respiratory rate, and axillary body temperature values at the time of admission to the emergency department, Geneva, Wells and PESI scores. In our study, no significant linear relationship was found between PDGF-β and D-Dimer levels in patients with PTE and mortality. Conclusion: The results obtained from this study, which investigated whether PDGF-B was a new prognostic biomarker for PTE, suggest that plasma PDGF-B levels are significantly higher in PTE cases and can aid in the diagnosis of PTE. However, PDGF-B cannot be used as a marker to predict prognosis

Abstract

Objective: Pulmonary thromboembolism (PTE) is a condition characterized by severe cardiopulmonary injury. There is a need for a cheap and reliable biochemical marker, which is also easily and rapidly accessible, with high specificity and sensitivity in the diagnosis of PTE. The PDGF ligand receptor system plays a role in the development of pulmonary hypertension and contributes to thickening of the vascular wall and increasing the wall tension. In the present study, we aimed to investigate whether plasma PDGF-B levels increase in patients with PTE and the diagnostic value of PDGF-B in PTE along with its relationship with mortality. Methods: This prospective clinical study was conducted in the emergency department of a tertiary university hospital between March 1st, 2020 and March 1st, 2021. A total of 44 patients diagnosed as having PTE in the emergency department (patient group) and 34 healthy volunteers without any chronic disease (control group) were included in our study. Results: The PDGF-β levels of the patients diagnosed as having PTE in the ED were found to be significantly higher than those of patients in the control group (Z=-2.015, p=0.044). There was no significant linear relationship between PDGF-β levels and age, gender, presence of chronic disease, systolic and diastolic blood pressure as well as peak heart rate, respiratory rate, and axillary body temperature values at the time of admission to the emergency department, Geneva, Wells and PESI scores. In our study, no significant linear relationship was found between PDGF-β and D-Dimer levels in patients with PTE and mortality. Conclusion: The results obtained from this study, which investigated whether PDGF-B was a new prognostic biomarker for PTE, suggest that plasma PDGF-B levels are significantly higher in PTE cases and can aid in the diagnosis of PTE. However, PDGF-B cannot be used as a marker to predict prognosis.

🔖

Bu Makaleye Atıf Yap

SAKÇİ, D., SAYHAN, M. B., SALT, Ö., DİBİRDİK, İ. (2022). A Novel Diagnostic Marker in Pulmonary Thromboembolism? Platelet-Derived Growth Factor –β. Dicle Tıp Dergisi, Cilt: 49 - Sayı: 1, 1–11. https://ajindex.com/articles/484887

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Bruzelius M, Iglesias MJ, Hong MG, et al. PDGFB, a new candidate plasma biomarker for venous thromboembolism: Results from the VEREMA affinity proteomics study. Blood. 2016; 128: e59-66
  2. Alhabibi AM, Eldewi DM, Wahab MAA, et al. Platelet-derived growth factor-beta as a new marker of deep venous thrombosis. J Res Med Sci. 2019; 24: 48
  3. Spronk HM, Cannegieter S, Morange P, et al. Theme 2: epidemiology, biomarkers, and imaging of venous thromboembolism (and postthrombotic syndrome). Thromb Res. 2015; 136 (Suppl 1): 8-12
  4. Yurdakul S, Aytekin S. Diagnostic algorithms in pulmonary hypertension. Anadolu Kardiyol Derg. 2010; 10 (Suppl 1): 14-26
  5. Sinan ÜY, Canbolat İP, Kaya A, et al. Pulmoner Arteriyal Hipertansiyon Hastalarında Serum D vitamini Düzeyleri. Dicle Med J. 2020; 47: 216-22
  6. Öztürk Ö, Akkaya A. Pulmonary arterial hypertension: pathogenesis. Journal of Süleyman Demirel University Faculty of Medicine. 2008; 15: 46-53
  7. Badesch DB, Champion HC, Gomez-Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54: 55-66
  8. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756-64
  9. Lee CH, Cheng CL, Lin LJ, et al. Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism. Circ J. 2011;7 5: 1998- 2004
  10. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756–64
  11. Keller K, Geyer M, Beule J, et al. Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular dysfunction in acute pulmonary embolism. Thorac Cancer. 2015; 6: 584-8
  12. Youssf ARI, Ismail MFM, ElGhamry R, et al. Diagnostic accuracy of D-dimer assay in suspected pulmonary embolism patients. Egypt J Chest Dis Tuberc. 2014; 63: 411-7
  13. Pulivarthi S, Gurram MK. Effectiveness of d dimer as a screening test for venous thromboembolism: An update. N Am J Med Sci. 2014; 6: 491-9
  14. Douma RA, le Gal GG, Söhne M, et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ. 2010; 340: c1475
  15. Jensen SB, Hindberg K, Solomon T, et al. Discovery of novel plasma biomarkers for future incident venous thromboembolism by untargeted synchronous precursor selection m